Objectives: Boceprevir is a first-generation direct-acting antiviral licensed for the treatment of hepatitis C infection. Sildenafil is an oral therapy for erectile dysfunction. As boceprevir is a potent inhibitor of CYP3A4, potential pharmacokinetic interactions may occur when it is coadministered with sildenafil. The aim of this study was to assess the pharmacokinetic profile of sildenafil and boceprevir when dosed separately and together in healthy volunteers.
Introduction
Several direct-acting antivirals (DAAs) have recently been approved for the treatment of hepatitis C virus (HCV) infection, including boceprevir, a PI recommended for the treatment of genotype-1 infection. 1 -4 Boceprevir is a potent, reversible inhibitor of the cytochrome P450 isoenzyme group (CYP450), and clinically relevant increases in the exposure of other drugs dependent on CYP450 have been observed when they are administered simultaneously. 5 As DAAs are used more widely, clinically relevant drugdrug interactions are likely to become apparent in patients receiving concomitant medication. Sildenafil, used for the management of erectile dysfunction, is metabolized via CYP450, and increases in plasma exposure have been described when it is administered with CYP450 inhibitors such as HIV PIs. 6 Therefore, increased exposure of sildenafil would be expected when it is administered with boceprevir; however, the magnitude of this interaction is unknown and unpredicted pharmacokinetic interactions often occur. The aim of this study was to assess the pharmacokinetic interactions of sildenafil and boceprevir when administered separately and together.
Methods

Subject selection
Healthy male volunteers, aged 18 -60 years, with no clinically significant abnormalities on screening laboratory testing and a BMI between 18 and 32 kg/m 2 were eligible to participate. Exclusion criteria included (Viagra TM ). Intensive pharmacokinetic sampling was performed over a 24 h period (at 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12 and 24 h post-dose). Subsequently, the study medication was stopped and the subjects attended a final follow-up visit. For safety monitoring, haematology and chemistry panels were undertaken throughout. A meal containing 20 g of fat was administered with all the witnessed doses.
A 25 mg dose of sildenafil (lower than the 50 mg or 100 mg generally used in clinical practice) was chosen for several reasons. First, this is the recommended dose when administered with CYP3A4 inhibitors. 7, 8 Second, given the unknown actual interactions between boceprevir and sildenafil, this dose was used in order to minimize potential adverse effects associated with excessively high peak concentrations. Finally, such an approach has been undertaken in similar pharmacokinetic studies. 6 
Analytical methods
Plasma concentrations of the individual isomers SCH534128 and SCH534129 of boceprevir were determined (PPD Global Central Labs, Middleton, WI, USA) and summated to give total boceprevir (SCH503034) concentrations. Plasma concentrations of sildenafil and its main metabolite N-desmethyl-sildenafil were analysed by a validated HPLC -tandem MS method at the University of Liverpool (UK). 9, 10 The lower limits of quantification for boceprevir SCH534128, boceprevir SCH534129, sildenafil and N-desmethyl-sildenafil were 5.20, 4.80, 2.60 and 1.275 ng/mL, respectively. Inter-and intra-assay precision did not exceed 10% for any compound.
Pharmacokinetic and statistical analysis
Pharmacokinetic parameters were calculated using non-compartmental methods (WinNonlin; Pharsight Corporation, Mountain View, CA, USA). The 95% CIs were constructed for the ratios of geometric means (GMs) of the AUC 24 for sildenafil and N-desmethyl-sildenafil or the AUC 8 for total boceprevir, the observed plasma C max values, the T max , the trough plasma concentration (C trough , defined as the concentration at 24 h after the observed dose for sildenafil and N-desmethyl-sildenafil or at 8 h after the observed dose for total boceprevir) and the t 1/2 (defined as the period of time required for the plasma drug concentration to be reduced by one-half from the C max ). All statistical calculations were performed and analysed using SPSS (version 22.0; SPSS Inc., Chicago, IL, USA). Within-subject changes in the assessed pharmacokinetic parameters between phase 3 versus the earlier phase were evaluated by assessment of the GM ratios (GMRs) and corresponding 95% CIs. The CIs were determined using logarithms of the individual GM values; the calculated values were then expressed as linear values. The boceprevir and sildenafil PK study 1813 
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Interpatient variability in the pharmacokinetic parameters was expressed as a coefficient of variation (CV) [(standard deviation/mean)×100].
Results
Patient characteristics and drug tolerability
Among the 13 subjects who completed all the study procedures, the ethnic origin was distributed as follows: six white (46%), four Asian (31%) and three black (23%) subjects. The median age was 36 years (range, 22 -47 years) and the median BMI was 26.2 kg/m 2 (range, 19.9 -30.6 kg/m 2 ). Study medications were well tolerated and no safety or laboratory concerns were observed. All patients reported 100% adherence to the therapy.
Plasma pharmacokinetic parameters over the study phases
The pharmacokinetic profile parameters for total boceprevir, sildenafil and N-desmethyl-sildenafil are shown in Table 1 . No significant changes in boceprevir exposure were observed between the study phases.
In the presence of boceprevir, the total exposure of sildenafil was increased by 2.7-fold (95% CI 2.1 -3.4) and the C max was increased by 1.9-fold (95% CI 1.5 -2.4). No changes in the elimination rate or T max for sildenafil were observed (Figure 1) . A 50% reduction in the C max of N-desmethyl-sildenafil was observed with no significant changes in elimination rate or T max . An increase in the ratio of the C max values of sildenafil to those of N-desmethylsildenafil was observed between phases 3 and 1 [8 (95% CI 6.3 -10) and 30 (95% CI 23 -41) in phase 1 versus phase 3, respectively].
Discussion
We assessed the pharmacokinetic interactions of sildenafil and boceprevir when administered together in healthy volunteers with no safety concerns observed.
An initial 25 mg oral dose of sildenafil was administered with no evidence of direct toxicity. The maximum plasma exposure of sildenafil observed was 279 ng/mL in phase 3. This is lower than the mean concentration observed after a single oral dose of 100 mg without enzyme-inhibiting drugs ( 440 ng/mL). 11 As we observed a 190% increase in the C max of sildenafil when it was administered with boceprevir, and assuming that the pharmacokinetic parameters were dose-proportional, one could expect C max values of approximately 1110 ng/mL if the 100 mg dose of sildenafil was to be administered with boceprevir. Although there is not a clearly defined maximum tolerated exposure of sildenafil, oral doses of 200 mg achieving C max values of 1150 ng/mL have resulted in an increased frequency and intensity of adverse events. 11, 12 Sildenafil and boceprevir were administered with food in all phases since the bioavailability of boceprevir depends greatly on its administration in the fed state. The absorption of sildenafil is slowed in the presence of food, resulting in the C max for sildenafil being reduced by 29%.
11 Therefore, our observations, in particular the increase in plasma C max , may underestimate these effects if sildenafil is administered without food, as often happens when treating erectile dysfunction. These findings suggest that 25 mg of sildenafil may be a suitable dose to commence in such subjects.
The increases in total plasma exposure (270%) and observed C max (190%) of sildenafil are similar in magnitude to the effects on sildenafil reported for other CYP3A4 inhibitors. The total plasma exposure of sildenafil has been shown to increase by 210% and 1110%, respectively, in the presence of the HIV PIs saquinavir and ritonavir. 7 The main route of metabolism of sildenafil is via Mora-Peris et al.
the CYP450 isoforms, predominantly CYP3A4 and to a lesser extent CYP2C9. Boceprevir is a strong inhibitor of CYP3A4/3A5 but does not inhibit CYP2C9. The increase in sildenafil exposure and plasma C max with no changes in absorption parameters (T max ) or elimination parameters (t 1/2 ) suggests the underlying mechanism to be a reduction in first-pass metabolism secondary to CYP3A4 inhibition by boceprevir. Since our study is limited by the assessment of pharmacokinetic parameters in healthy volunteers rather than HCV-infected individuals, this inhibition of CYP3A4 may occur in addition to a previously observed moderate reduction in CYP3A4 activity in HCV-infected patients receiving IFN/ribavirin therapy. 13 Interestingly, the exposure of N-desmethyl-sildenafil, the main metabolite of sildenafil, although unchanged, was reduced in proportion to the maximum sildenafil exposure. These results suggest the metabolic pathway for the production of the N-desmethyl-sildenafil metabolite is not solely through CYP3A4, and that there might be an involvement of other pathways that boceprevir may not have an effect on, such as CYP2C9.
Several other DAAs, such as telaprevir, paritaprevir/ritonavir and simeprevir, also affect the hepatic CYP450 isoenzyme group. 14 -16 As DAAs are increasingly used in HCV treatment, drug -drug interactions will continue to be of clinical relevance, and future work to assess such interactions remains imperative in order to maintain the safest approaches in clinical practice.
